Filing Flows

Filing Flows › Protagonist Therapeutics (PTGX) › Next earnings date

Protagonist Therapeutics (PTGX) earnings: beat the estimate

Protagonist Therapeutics (PTGX) reported on Nov 5, 2026 and beat the EPS estimate: $3.07 against $2.66 (+15.4%). Revenue was $274M for Q3 2026, 58× year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+15.4% vs estimate
Beat rate80%

The last report

Protagonist Therapeutics reported revenue of $274M for the third quarter 2026 (58× Y/Y), net earnings $220M. How it makes money → · Every quarter →

Protagonist Therapeutics: EPS against the estimate, last 5 reportsProtagonist Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.64−$0.62Nov 25−$0.54−$0.69Feb 26−$0.65$0.05May 26$1.93$2.29Aug 26$2.66$3.07Nov 26
Latest (Nov 26): Estimate $2.66, Reported $3.07.

Protagonist Therapeutics' latest quarter

Protagonist Therapeutics, Q3 2026: revenue $274M (58× year over year), operating margin 79.6%, net earnings $220M, operating cash flow −$23.2M. The chart follows the revenue to costs, profit and cash.

Questions

Did Protagonist Therapeutics beat earnings?

Protagonist Therapeutics (PTGX) reported on Nov 5, 2026 and beat the EPS estimate: $3.07 against $2.66 (+15.4%).

When does PTGX report earnings?

The next date is not set yet.

Does Protagonist Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.